Arsenic induces telomerase expression and maintains telomere length in human cord blood cells

Toxicology

Volumn 260, Issue 1-3, 2009, Pages 132-141

  Ferrario, Daniele ^a   Collotta, Angelo ^a   Carfi, Maria ^a   Bowe, Gerard ^a   Vahter, Marie ^b   Hartung, Thomas ^c   Gribaldo, Laura ^a  

^a JOINT RESEARCH CENTRE   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Arsenic; BSO; DMPO; hTERT; In vitro; ROS

Indexed keywords

5,5 DIMETHYL 1 PYRROLINE 1 OXIDE; ARSENIC; ARSENIC TRIOXIDE; ARSENOUS ACID DERIVATIVE; BUTHIONINE SULFOXIMINE; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; TELOMERASE;

APOPTOSIS; ARTICLE; BLOOD CELL; CELL DIFFERENTIATION; CELL GROWTH; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EVALUATION; FEMALE; GENE OVEREXPRESSION; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NECROSIS; ONCOGENE C MYC; ONCOGENE MYC; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SEX DIFFERENTIATION; TELOMERE; UMBILICAL CORD BLOOD; WESTERN BLOTTING;

APOPTOSIS; ARSENITES; BLOTTING, WESTERN; BUTHIONINE SULFOXIMINE; CELL SURVIVAL; CYCLIC N-OXIDES; ENZYME INDUCTION; ENZYME INHIBITORS; FEMALE; FETAL BLOOD; FLOW CYTOMETRY; FREE RADICAL SCAVENGERS; GLUTATHIONE; HUMANS; MALE; PROTO-ONCOGENE PROTEINS C-MYC; RAS PROTEINS; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEX FACTORS; SODIUM COMPOUNDS; STEM CELLS; TELOMERASE; TELOMERE;

EID: 67349274178     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2009.03.019     Document Type: Article

References (75)

1. Abernathy C.O., Liu Y.P., Longfellow D., Aposhian H.V., Beck B., Fowler B., Goyer R., Menzer R., Rossman T., Thompson C., and Waalkes M. Arsenic: health effects, mechanisms of actions, and research issues. Environ. Health Perspect. 107 7 (1999) 593-597
2. Afzal M., Afzal A., Jones A., and Armstrong D. A rapid method for the quantification of GSH and GSSG in biological samples. In: Armstrong D. (Ed). Oxidative Stress Biomarker and Antioxidant Protocols (2002), Humana Press, New Jersey 117-122
3. Allen R.G., and Tresini M. Oxidative stress and gene regulation. Free Radic. Biol Med. 28 3 (2000) 463-499
4. Allsopp R.C., Morin G.B., DePinho R., Harley C.B., and Weissman I.L. Telomerase is required to slow telomere shortening and extend replicative lifespan of HSCs during serial transplantation. Blood 102 2 (2003) 517-520
5. Allsopp R.C., Morin G.B., Horner J.W., DePinho R., Harley C.B., and Weissman I.L. Effect of TERT over-expression on the long-term transplantation capacity of hematopoietic stem cells. Nat. Med. 4 (2003) 369-371
6. Andrew A.S., Karagas M.R., and Hamilton J.W. Decreased DNA repair gene expression among individuals exposed to arsenic in United States drinking water. Int. J. Cancer 104 3 (2003) 263-268
7. Andrew A.S., Burgess J.L., Meza M.M., Demidenko E., Waugh M.G., Hamilton J.W., and Karagas M.R. Arsenic exposure is associated with decreased DNA repair in vitro and in individuals exposed to drinking water arsenic. Environ. Health Perspect. 114 8 (2006) 1193-1198
8. Au W.Y., Kumana C.R., Kou M., Mak R., Chan G.C., Lam C.W., and Kwong Y.L. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood 102 1 (2003) 407-408
9. Barchowsky A., Roussel R.R., Klei L.R., James P.E., Ganju N., Smith K.R., and Dudek E.J. Low levels of arsenic trioxide stimulate proliferative signals in primary vascular cells without activating stress effector pathways. Toxicol. Appl. Pharmacol. 159 1 (1999) 65-75
10. Barrett J.C., Lamb P.W., Wang T.C., and Lee T.C. Mechanisms of arsenic-induced cell transformation. Biol Trace Elem. Res. 21 (1989) 421-429
11. Blackburn E.H. Telomeres and telomerase. Keio J. Med. 49 2 (2000) 59-65
12. Blackburn E.H. Telomeres and telomerase. Blood 90 1 (2000) 182-193
13. Bouffler S.D., Blasco M.A., Cox R., and Smith P.J. Telomeric sequences, radiation sensitivity and genomic instability. Int. J. Radiat. Biol. 77 10 (2001) 995-1005
14. Burns L.A., and Munson A.E. Reversal of gallium arsenide-induced suppression of the antibody-forming cell response by vehicle supernatants. II. Nature and identification of reversing factors. J. Pharmacol. Exp. Ther. 265 1 (1993) 150-158
15. Campbell L.J., Fidler C., Eagleton H., Peniket A., Kusec R., Gal S., Littlewood T.J., Wainscoat J.S., and Boultwood J. hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia. Leukemia 2006 4 (2006) 671-679
16. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88 3 (1996) 1052-1061
17. Chen J. Senescence and functional failure in hematopoietic stem cells. Exp. Hematol. 32 11 (2004) 1025-1032
18. Chen Y.C., Lin-Shiau S.Y., and Lin J.K. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J. Cell Physiol. 177 2 (1998) 324-333
19. Chen G.C., Guan L.S., Hu W.L., and Wang Z.Y. Functional repression of estrogen receptor a by arsenic trioxide in human breast cancer cells. Anticancer Res. 22 2A (2002) 633-638
20. Chiu C.P., Dragowska W., Kim N.W., Vaziri H., Yui J., Thomas T.E., Harley C.B., and Lansdorp P.M. Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow. Stem Cells 14 2 (1996) 239-248
21. Chow S.K., Chan J.Y., and Fung K.P. Suppression of cell proliferation and regulation of estrogen receptor alpha signaling pathway by arsenic trioxide on human breast cancer MCF-7 cells. J. Endocrinol. 182 2 (2004) 325-337
22. Cimino-Reale G., Ferrario D., Casati B., Brustio R., Diodovich C., Collotta A., Vahter M., and Gribaldo L. Combined in utero and juvenile exposure of mice to arsenate and atrazine in drinking water modulates gene expression and clonogenicity of myeloid progenitors. Toxicol. Lett. 180 1 (2008) 59-66
23. Concha G., Vogler G., Lezcano D., Nermell B., and Vahter M. Exposure to inorganic arsenic metabolites during early human development. Toxicol. Sci. 44 2 (1998) 185-190
24. Davey J.C., Bodwell J.E., Gosse J.A., and Hamilton J.W. Arsenic as an endocrine disruptor: effects of arsenic on estrogen receptor-mediated gene expression in vivo and in cell culture. Toxicol. Sci. 98 1 (2007) 75-86
25. de Magalhães J.P., and Toussaint O. Telomeres and telomerase: a modern fountain of youth?. Rejuvenation Res. 7 2 (2004) 126-133
26. Dong C.K., Masutomi K., and Hahn W.C. Telomerase: regulation, function and transformation. Crit. Rev. Oncol. Hematol. 54 2 (2005) 85-93
27. Dubik D., and Shiu R.P. Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 7 8 (1992) 1587-1594
28. Engelhardt M., Kumar R., Albanell J., Pettengell R., Han W., and Moore M.A. Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells. Blood 90 1 (1997) 182-193
29. Engelhardt M., Mackenzie K., Drullinsky P., Silver R.T., and Moore M.A. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Cancer Res. 60 3 (2000) 610-617
30. Engelhardt M., Mackenzie K., Drullinsky P., Silver R.T., and Moore M.A. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Environ. Res. 101 3 (2000) 349-355
31. Ferrario D., Croera C., Brustio R., Collotta A., Bowe G., Vahter M., and Gribaldo L. Toxicity of inorganic arsenic and its metabolites on haematopoietic progenitors "in vitro": comparison between species and sexes. Toxicology 249 2-3 (2008) 102-108
32. Golub M.S., Macintosh M.S., and Baumrind N. Developmental and reproductive toxicity of inorganic arsenic: animal studies and human concerns. J. Toxicol. Environ. Health B Crit. Rev. 1 3 (1998) 199-241
33. Hall A.H. Chronic arsenic poisoning. Toxicol. Lett. 128 1-3 (2002) 69-72
34. Holt S.E., and Shay J.W. Role of telomerase in cellular proliferation and cancer. J. Cell Physiol. 180 1 (1999) 10-18
35. Hu Y., Jin X., and Snow E.T. Effect of arsenic on transcription factor AP-1 and NF-kappaB DNA binding activity and related gene expression. Toxicol. Lett. 133 1 (2002) 33-45
36. IARC, 2004. Some drinking water disinfectants and contaminants, including arsenic. IARC Monograph on the Evaluation of Carcinogenic Risks to Humans, vol. 84. International Agency for Research on Cancer, Lyon, France, pp. 209-214.
37. Ishibashi, T., Lippard, S.J., 1998. Telomere loss in cells treated with cisplatin. Proc. Natl. Acad. Sci. U.S.A. 14, 95(8) 4219-4223.
38. Jiang W., Kahn S.M., Zhou P., Zhang Y.J., Cacace A.M., Infante A.S., Doi S., Santella R.M., and Weinstein I.B. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene 8 12 (1993) 3447
39. Jin Y., Xi S., Li X., Lu C., Li G., Xu Y., Qu C., Niu Y., and Sun G. Arsenic speciation transported through the placenta from mother mice to their newborn pups. Environ. Res. 101 3 (2006) 349-355 (Epub 2006 Feb 2)
40. Kendall S.D., Linardic C.M., Adam S.J., and Counter C.M. A network of genetic events sufficient to convert normal human cells to a tumorigenic state. Cancer Res. 65 21 (2005) 9824-9828
41. Leteurtre F., Li X., Guardiola P., Le Roux G., Sergere J.C., Richard P., Carosella E.D., and Gluckman E. Accelerated telomere shortening and telomerase activation in Fanconi's anaemia. Br. J. Haematol. 105 4 (1999) 883-893
42. Liao C.T., Tung-Chieh Chang J., Wang H.M., Chen I.H., Lin C.Y., Chen T.M., Hsieh L.L., and Cheng A.J. Telomerase as an independent prognostic factor in head and neck squamous cell carcinoma. Head Neck 6 6 (2004) 504-512
43. Lindberg A.L., Ekström E.C., Nermell B., Rahman M., Lönnerdal B., Persson L.A., and Vahter M. Gender and age differences in the metabolism of inorganic arsenic in a highly exposed population in Bangladesh. Environ. Res. 106 1 (2008) 110-120
44. Liu L., Trimarchi J.R., Navarro P., Blasco M.A., and Keefe D.L. Oxidative stress contributes to arsenic-induced telomere attrition, chromosome instability and apoptosis. J. Biol. Chem. 278 (2003) 31998-32004
45. Liu J., Xie Y., Cooper R., Ducharme D.M., Tennant R., Diwan B.A., and Waalkes M.P. Transplacental exposure to inorganic arsenic at a hepatocarcinogenic dose induces fetal gene expression changes in mice indicative of aberrant estrogen signaling and disrupted steroid metabolism. Toxicol. Appl. Pharmacol. 220 3 (2007) 284-291
46. 3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res. 61 14 (2001) 5432-5440
47. McEachern M.J., Iyer S., Fulton T.B., and Blackburn E.H. Telomere fusions caused by mutating the terminal region of telomeric DNA. Proc. Natl. Acad. Sci. U.S.A. 97 21 (2000) 11409-11414
48. National Research Council, 1999/2001. Arsenic in drinking water. National Academy Press, Washington, DC, USA.
49. Patterson, R., Vega, L., Trouba, K., Bortner, C., Germolec, D., 2004. Arsenic-induced alterations in the contact hypersensitivity response in Balb/c mice. Toxicol. Appl. Pharmacol. 1 198(3) 434-443.
50. Pi, J., Kumagai, Y., Sun, G., Yamauchi, H., Yoshida, T., Iso, H., Endo, A., Yu, L., Yuki, K., Miyauchi, T., Shimojo, N., 2000. Decreased serum concentrations of nitric oxide metabolites among Chinese in an endemic area of chronic arsenic poisoning in inner Mongolia. Free Radic. Biol. Med. 1 28(7) 1137-1142.
51. Ramírez R., Carracedo J., Jiménez R., Canela A., Herrera E., Aljama P., and Blasco M.A. Massive telomere loss is an early event of DNA damage-induced apoptosis. J. Biol. Chem. 278 2 (January) (2003) 836-842
52. Sakurai T., Kojima C., Ochiai M., Ohta T., and Fujiwara K. Evaluation of in vivo acute immunotoxicity of a major organic arsenic compound arsenobetaine in seafood. Int. Immunopharmacol. 4 2 (2004) 179-184
53. Sakurai T., Ohta T., Tomita N., Kojima C., Hariya Y., Mizukami A., and Fujiwara K. Evaluation of immunotoxic and immunodisruptive effects of inorganic arsenite on human monocytes/macrophages. Int. Immunopharmacol. 6 2 (2006) 304-315
54. Shay J.W., Zou Y., Hiyama E., and Wright W.E. Telomerase and cancer. Hum. Mol. Genet. 10 7 (2001) 677-685
55. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89 9 (1997) 3354-3360
56. Slijepcevic P., and Bryant P.E. Absence of terminal telomeric FISH signals in chromosomes from immortal Chinese hamster cells. Cytogenet. Cell. Genet. 69 1-2 (1995) 87-89
57. Slijepcevic P., and Bryant P.E. Absence of terminal telomeric FISH signals in chromosomes from immortal Chinese hamster cells. Stem Cells 22 5 (1995) 741-749
58. Soto-Peña G.A., Luna A.L., Acosta-Saavedra L., Conde P., López-Carrillo L., Cebrián M.E., Bastida M., Calderón-Aranda E.S., and Vega L. Assessment of lymphocyte subpopulations and cytokine secretion in children exposed to arsenic. FASEB J. 20 6 (2006) 779-781
59. Stoica A., Pentecost E., and Martin M.B. Effects of arsenite on estrogen receptor-alpha expression and activity in MCF-7 breast cancer cells. Endocrinology 141 10 (2000) 3595-3602
60. Trouba K.J., Wauson E.M., and Vorce R.L. Sodium arsenite-induced dysregulation of proteins involved in proliferative signaling. Toxicol. Appl. Pharmacol. 164 2 (2000) 161-170
61. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., and Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3 7 (2002) RESEARCH0034
62. Vega, L., Montes de Oca, P., Saavedra, R., Ostrosky-Wegman, P., 2004. Helper T cell subpopulations from women are more susceptible to the toxic effect of sodium arsenite in vitro. Toxicology. 1 199(2-3) 121-128.
63. Waalkes M.P., Liu J., and Diwan B.A. Transplacental arsenic carcinogenesis in mice. Toxicol. Appl. Pharmacol. 222 3 (2007) 271-280
64. Waalkes M.P., Liu J., Ward J.M., and Diwan B.A. Mechanisms underlying arsenic carcinogenesis: hypersensitivity of mice exposed to inorganic arsenic during gestation. Toxicology 198 1-3 (2004) 31-38
65. Waalkes M.P., Liu J., Ward J.M., and Diwan B.A. Animal models for arsenic carcinogenesis: inorganic arsenic is a transplacental carcinogen in mice. Toxicol. Appl. Pharmacol. 198 3 (2004) 377-384
66. Waalkes M.P., Liu J., Ward J.M., Powell D.A., and Diwan B.A. Urogenital carcinogenesis in female CD1 mice induced by in utero arsenic exposure is exacerbated by postnatal diethylstilbestrol treatment. Cancer Res. 66 3 (2006) 1337-1345
67. Waris G., and Ahsan H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J. Carcinogen. 11 5 (2006) 14
68. WHO Arsenic and Arsenic Compound, 2001. Environmental Health Criteria, vol. 224. World Health Organization, Geneva.
69. Wu K.J., Grandori C., Amacker M., Simon-Vermot N., Polack A., Lingner J., and Dalla-Favera R. Direct activation of TERT transcription by c-MYC. Nat. Genet. 21 2 (1999) 220-224
70. Wu M.M., Chiou H.Y., Ho I.C., Chen C.J., and Lee T.C. Gene expression of inflammatory molecules in circulating lymphocytes from arsenic-exposed human subjects. Environ. Health Perspect. 111 11 (2003) 1429-1438
71. Xu Y., Wang Y., Zheng Q., Li X., Li B., Jin Y., Sun X., and Sun G. Association of oxidative stress with arsenic methylation in chronic arsenic-exposed children and adults. Toxicol. Appl. Pharmacol. 232 1 (2008) 142-149
72. Yih L.H., and Lee T.C. Arsenite induces p53 accumulation through an ATM-dependent pathway in human fibroblasts. Cancer Res. 60 22 (2000) 6346-6352
73. Yoshida T., Yamauchi H., and Fan Sun G. Chronic health effects in people exposed to arsenic via the drinking water: dose-response relationships in review. Toxicol. Appl. Pharmacol. 198 3 (2004) 243-252
74. Zhang T.C., Schmitt M.T., and Mumford J.L. Effects of arsenic on telomerase and telomeres in relation to cell proliferation and apoptosis in human keratinocytes and leukemia cells in vitro. Carcinogenesis 24 11 (2003) 1811-1817
75. Zhang Y., Cao E.H., Liang X.Q., and Qin J.F. Increasing sensitivity to arsenic trioxide-induced apoptosis by altered telomere state. Eur. J. Pharmacol. 474 2-3 (2003) 141-147